Figure 3.

Toxicity profiles based on adverse events (A) and immune-related adverse events (B). Pooled incidences and 95% confidence intervals of grade 1–5 events for each treatment are at bottom and that of grade 3–5 events are at top of the figure. Each cell of the safety profiles shows pooled relative risks and 95% confidence intervals for grade 1–5 (light grey cell) and grade 3–5 (dark grey cell) events; significant results are in bold. For instance, as for PD-1 in Figure 3A, patients receiving PD-1 had a lower risk of grade 1-5 adverse events than those receiving PD-1 + chemotherapy (RR: 0.13, 95% CI: 0.08–0.21). CT: chemotherapy; PD–1: programmed death–1 receptor inhibitor; PD–L1: programmed death ligand–1 inhibitor; CTLA–4: cytotoxic T lymphocyte associated antigen inhibitor.